Veloce BioPharma LLC

Quick facts

Phase 2 pipeline

• 2014-ALC-919-US · Oncology
  This drug targets the PD-1 receptor to modulate the immune response.
• VBP-245
• VBP-245 Topical Gel
• VBP-926

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Veloce BioPharma LLC portfolio CI brief
• Veloce BioPharma LLC pipeline updates RSS